Integra LifeSciences (NASDAQ:IART) Shares Gap Down - Time to Sell?

Key Points

• Integra LifeSciences shares fell sharply, opening at $12.77 versus a prior close of $13.33. The decline came despite third-quarter adjusted EPS of $0.59 exceeding the $0.56 consensus estimate.
• Results were mixed: revenue rose 2.3% to $411.2 million but missed estimates, while flooding caused approximately $7 million in lost revenue and Tissue Reconstruction sales declined 2.2%.
• The company reaffirmed its 2026 guidance and completed a $2.1 billion refinancing to extend maturities, but analysts remain cautious; the consensus rating is “Reduce” and several firms cut their price targets to $15.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) gapped down prior to trading on Wednesday. The stock had previously closed at $13.33, but opened at $12.77. Integra LifeSciences shares last traded at $13.27, with a volume of 71,069 shares trading hands.

Integra LifeSciences News Summary

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Third-quarter adjusted EPS was $0.59, above the $0.56 consensus and up from $0.54 a year earlier. GAAP EPS improved to $0.19 from a $0.07 loss, while operating cash flow rose to $96 million. Integra LifeSciences surpasses Q3 earnings estimates
• Positive Sentiment: Specialty Surgery remained a growth driver. Segment revenue increased 3.9% year over year, with organic Neurosurgery sales up 6.5%, helping offset weakness elsewhere. Integra also reduced its leverage ratio to 3.8x and reported $1.5 billion in net debt. Integra third-quarter 2026 financial results
• Positive Sentiment: Debt refinancing reduces near-term refinancing risk. Integra completed a $2.1 billion refinancing that extends maturities and increases covenant flexibility. The transaction is intended to support liquidity and continued deleveraging. Integra refinancing transactions
• Neutral Sentiment: Full-year guidance was reaffirmed. Integra maintained 2026 revenue guidance of $1.634 billion to $1.654 billion and adjusted EPS guidance of $2.30 to $2.40. Fourth-quarter revenue is expected to range from $413 million to $433 million, with adjusted EPS of $0.61 to $0.71.
• Negative Sentiment: Revenue fell short of estimates and growth was limited. Third-quarter revenue increased 2.3% to $411.2 million, below the $413.2 million analyst estimate. The company expects fourth-quarter reported revenue to decline between 0.5% and 5.2% year over year. Integra Q3 key metrics versus estimates
• Negative Sentiment: Flood damage and segment weakness remain concerns. Cincinnati facility flooding reduced quarterly revenue by approximately $7 million, while Tissue Reconstruction revenue declined 2.2%. The refinancing is also expected to increase interest costs by near the high end of the previously indicated 100-to-200-basis-point range.
• Negative Sentiment: Analyst sentiment weakened. Truist lowered its price target for IART to $15 from $19, adding pressure to the stock’s outlook. Truist cuts Integra price target

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. BMO Capital Markets dropped their price objective on shares of Integra LifeSciences from $18.00 to $15.00 and set a "market perform" rating for the company in a research note on Monday, October 5th. Weiss Ratings downgraded shares of Integra LifeSciences from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, October 2nd. Citigroup restated a "neutral" rating and set a $15.00 target price (down from $19.00) on shares of Integra LifeSciences in a research report on Monday, October 5th. Truist Financial lowered their target price on shares of Integra LifeSciences from $19.00 to $15.00 and set a "hold" rating on the stock in a report on Wednesday, October 14th. Finally, UBS Group assumed coverage on shares of Integra LifeSciences in a report on Tuesday, July 28th. They set a "neutral" rating and a $19.00 target price on the stock. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Integra LifeSciences presently has an average rating of "Reduce" and a consensus target price of $16.71.

Integra LifeSciences Trading Down 7.4%

The business has a 50-day moving average price of $15.67 and a two-hundred day moving average price of $15.55. The stock has a market capitalization of $959.72 million, a P/E ratio of -138.21, a P/E/G ratio of 0.71 and a beta of 1.21. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.03. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%. The company had revenue of $411.18 million for the quarter, compared to analyst estimates of $413.16 million. During the same period in the prior year, the firm posted ($0.07) EPS. On average, analysts expect that Integra LifeSciences Holdings Corporation will post 2.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

A number of large investors have recently bought and sold shares of IART. Paradigm Capital Management Inc. NY raised its position in Integra LifeSciences by 50.6% during the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company's stock valued at $37,800,000 after purchasing an additional 1,347,700 shares in the last quarter. Wellington Management Group LLP lifted its stake in Integra LifeSciences by 12.4% during the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company's stock worth $26,241,000 after purchasing an additional 160,814 shares during the last quarter. Bank of America Corp DE lifted its stake in Integra LifeSciences by 71.4% during the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company's stock worth $13,325,000 after purchasing an additional 589,408 shares during the last quarter. Glenmede Trust Co. NA boosted its holdings in shares of Integra LifeSciences by 27.4% in the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company's stock valued at $9,276,000 after purchasing an additional 211,774 shares in the last quarter. Finally, Access Investment Management LLC boosted its holdings in shares of Integra LifeSciences by 72.0% in the 1st quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company's stock valued at $6,034,000 after purchasing an additional 268,085 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra's neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.